Sector News

Leo Pharma’s dermatology innovation challenge gathers ideas focused on skin of color

November 1, 2020
Life sciences

Leo Pharma’s latest “hackathon” brought together scientists and entrepreneurs to find dermatology solutions for people of color.

The third “Hacking Dermatology Innovation Challenge” tasked participants to focus on the specific challenges faced by “patients with skin of color.” The partnership between Leo’s research and development unit and nonprofit skin advocacy group Advancing Innovation in Dermatology (AID)  named five winning teams over the weekend.

Research has shown that diagnosing skin of color can be more difficult because of darker pigmentation as well as differences in the way inflammation presents. The “Hacking Dermatology” contest that ran through Sunday hopes to help with the issue.

Some of the ideas Leo was looking for included shortening diagnostic delays, making diagnoses more accurate, offering better personalized care, making clinical trials more diverse and providing empowerment and education that could lead to equity in technology advancements, Michael Sierra, vice president of the Leo Science & Tech Hub, said.

MIT Hacking Medicine is also part of this year’s challenge. While this is the third “Hacking Dermatology” challenge, it’s the first time the challenge was completely virtual due to the COVID-19 pandemic.

“What’s really cool about entrepreneurs and scientists is that most of us are introverts, right, so working in a virtual setting isn’t the biggest challenge. We’ve seen quite a good turnout,” Sierra said.

The three-day event began with a pitch session. Contributors then presented and competed over two days, with the winner announced Oct. 25.

The winning teams received $15,000 in grants and a chance to move to an advanced challenge with another $25,000 prize. The teams are mentored by volunteers from a variety of backgrounds and get access to resources that could potentially bring the winning projects to life.

The project was born in 2018 after Leo brought together key opinion leaders and scientists to consider innovation challenges in the field. Hacking Dermatology was created as a way to help healthcare professionals, entrepreneurs and others solve the real problems they’ve discovered, William Ju, M.D., one of the challenge founders and president and founder of AID, said.

“You can come to look and promote your idea, refine it, find key members and move it forward into something that is very tangible,” he said.

Over the past few years, Leo Pharma has purchased dermatology businesses including Bayer’s prescription unit and Astellas’ portfolio. Leo also markets plaque psoriasis drugs Enstilar and Taclonex.

by Sharon Klahr Coey

Source: fiercepharma.com

comments closed

Related News

November 19, 2022

Sequana announces results from study of direct sodium removal

Life sciences

Sequana, a company focusing on liver disease, heart failure and cancer has announced positive top-line results from SAHARA – the phase 2a study using its first-generation direct sodium removal (DSR) product, DSR 1.0. Data from ten evaluable diuretic-resistant heart failure patients confirmed long-lasting clinical benefits.

November 19, 2022

Bristol Myers Squibb opens 125-acre biologics campus in Dublin

Life sciences

Bristol Myers Squibb has officially opened its Cruiserath Biologics site in Dublin. The site, which represents a $1bn investment – was officially opened by the company’s chief executive officer, Giovanni Caforio, who arrived from New York, and site general manager Pádraig Keane.

November 19, 2022

Pharma must stay the course on Twitter as docs are not abandoning the platform yet: Report

Life sciences

Like it or loathe it, and whatever its new direction, Twitter is still a powerful platform for doctors, and pharma should not abandon the troubled social media site yet, according to a new report from healthcare consultants at ZoomRx.